Larvol Delta - A-Phase-1a1b-DoseEscalation-and-Expansion-Study-of-18577LuLuFAP2286-Radioligand-Therapy-in-Combination-with-Dual-Immune-Checkpoint-Blockade-Nivolumab-and-Ipilimumab-in-Patients-with-Unresectable-or-Advanced-Malignant-Pleural-Mesothelioma-MPM

Yervoy (ipilimumab) - BMS

lutetium Lu 177 rofapitide tetraxetan (AAA614) - Novartis

Opdivo (nivolumab) - Ono Pharmaceutical, BMS

https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12626000505303

Apr 24, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next